JP7046959B2 - チエノピリミジン誘導体及び医薬におけるその使用 - Google Patents

チエノピリミジン誘導体及び医薬におけるその使用 Download PDF

Info

Publication number
JP7046959B2
JP7046959B2 JP2019538620A JP2019538620A JP7046959B2 JP 7046959 B2 JP7046959 B2 JP 7046959B2 JP 2019538620 A JP2019538620 A JP 2019538620A JP 2019538620 A JP2019538620 A JP 2019538620A JP 7046959 B2 JP7046959 B2 JP 7046959B2
Authority
JP
Japan
Prior art keywords
mixture
methyl
mmol
methoxyphenyl
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019538620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505356A (ja
JP2020505356A5 (enExample
Inventor
タン、ワンジュン
ヤン、シンイェ
グ、ツェン
リ、チェンル
ツァン、ゾンユアン
ワン、ジフ
ワン、シャオジュン
ツァン、インジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2020505356A publication Critical patent/JP2020505356A/ja
Publication of JP2020505356A5 publication Critical patent/JP2020505356A5/ja
Application granted granted Critical
Publication of JP7046959B2 publication Critical patent/JP7046959B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019538620A 2017-01-22 2018-01-22 チエノピリミジン誘導体及び医薬におけるその使用 Active JP7046959B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710052275.3 2017-01-22
CN201710052275 2017-01-22
PCT/CN2018/073581 WO2018133858A1 (en) 2017-01-22 2018-01-22 Thienopyrimidine derivative and use thereof in medicine

Publications (3)

Publication Number Publication Date
JP2020505356A JP2020505356A (ja) 2020-02-20
JP2020505356A5 JP2020505356A5 (enExample) 2021-02-18
JP7046959B2 true JP7046959B2 (ja) 2022-04-04

Family

ID=62908330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538620A Active JP7046959B2 (ja) 2017-01-22 2018-01-22 チエノピリミジン誘導体及び医薬におけるその使用

Country Status (8)

Country Link
US (1) US10759812B2 (enExample)
EP (1) EP3571205B1 (enExample)
JP (1) JP7046959B2 (enExample)
KR (1) KR102577824B1 (enExample)
CN (1) CN108341830B (enExample)
AU (1) AU2018209006B2 (enExample)
CA (1) CA3049816A1 (enExample)
WO (1) WO2018133858A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201807077RA (en) 2016-03-02 2018-09-27 Gilead Apollo Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CN110382503B (zh) 2017-03-03 2022-07-19 吉利德科学公司 制备acc抑制剂及其固体形式的方法
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
TW201910338A (zh) * 2017-07-26 2019-03-16 大陸商南京聖和藥業股份有限公司 作為acc抑制劑的化合物及其應用
US12220415B2 (en) 2018-02-28 2025-02-11 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
CN109810085B (zh) * 2019-04-19 2019-07-19 上海皓元生物医药科技有限公司 Acc抑制剂及其中间体的制备方法
CN111848678A (zh) * 2019-04-30 2020-10-30 正大天晴药业集团股份有限公司 含磷类噻吩并嘧啶衍生物
EP3995498A4 (en) * 2019-07-02 2023-03-01 Sunshine Lake Pharma Co., Ltd. THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE
AR119594A1 (es) * 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
US20240002394A1 (en) * 2020-11-24 2024-01-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Deuterium-modified thienopyridone compound
WO2022166761A1 (zh) * 2021-02-07 2022-08-11 正大天晴药业集团股份有限公司 噻吩并嘧啶衍生物
TW202400151A (zh) * 2022-05-26 2024-01-01 大陸商廣東東陽光藥業股份有限公司 噻吩並嘧啶類化合物的晶型及其用途
CN117126175B (zh) * 2022-05-26 2025-12-05 广东东阳光药业股份有限公司 噻吩并嘧啶类化合物的共晶及其用途
CN117126174B (zh) * 2022-05-26 2025-12-05 广东东阳光药业股份有限公司 噻吩并嘧啶类化合物的共晶及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533281A (ja) 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2015007451A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016096115A1 (en) 2014-12-17 2016-06-23 Gilead Sciences, Inc. Hydroxy containing fxr (nr1h4) modulating compounds
WO2016112305A1 (en) 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
CA2644996A1 (en) 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
JP6417402B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
JP6417401B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
AU2014262547A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2015003881A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
AU2016361412A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
WO2017147161A1 (en) 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
CN107698603B (zh) 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
US11142531B2 (en) 2017-03-24 2021-10-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof
CN110431143B (zh) 2017-03-24 2022-08-12 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物及其制备方法和用途
CN110709402B (zh) 2017-06-15 2022-05-10 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533281A (ja) 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2015007451A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016096115A1 (en) 2014-12-17 2016-06-23 Gilead Sciences, Inc. Hydroxy containing fxr (nr1h4) modulating compounds
WO2016112305A1 (en) 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Acta Poloniae Pharmaceutica，2013年，Vol.70(5)，p.833-849

Also Published As

Publication number Publication date
WO2018133858A1 (en) 2018-07-26
US20190352311A1 (en) 2019-11-21
KR102577824B1 (ko) 2023-09-13
CN108341830B (zh) 2021-03-02
KR20190110575A (ko) 2019-09-30
EP3571205A4 (en) 2020-06-03
JP2020505356A (ja) 2020-02-20
CN108341830A (zh) 2018-07-31
CA3049816A1 (en) 2018-07-26
AU2018209006A1 (en) 2019-07-25
EP3571205A1 (en) 2019-11-27
US10759812B2 (en) 2020-09-01
EP3571205B1 (en) 2023-08-30
AU2018209006B2 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
JP7046959B2 (ja) チエノピリミジン誘導体及び医薬におけるその使用
KR102368298B1 (ko) 질소-함유 트라이사이클릭 화합물, 및 의약에서 이의 용도
US11208418B2 (en) Nitrogenous tricyclic compounds and uses thereof in medicine
US11787803B2 (en) Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
JP2021535141A (ja) αｖβ６インテグリンの阻害
JP2017512809A (ja) 二環式縮合ヘテロアリールまたはアリール化合物およびｉｒａｋ４阻害剤としてのそれらの使用
CN105732636A (zh) 杂芳化合物及其在药物中的应用
KR20240065201A (ko) 이환형 케톤 화합물 및 이의 사용 방법
CN105399756B (zh) Btk抑制剂及其用途
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
AU2019452636A1 (en) Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
JP2015507001A (ja) 三環式化合物及びその使用方法
CN113563246B (zh) 取代的氮杂五元环类衍生物及其在药物中的应用
HK40011745B (en) Thienopyrimidine derivative and use thereof in medicine
HK40011745A (en) Thienopyrimidine derivative and use thereof in medicine
RU2797922C2 (ru) Бициклические кетоны и способы их применения
TW202425972A (zh) 三環類化合物及其製備方法和應用
TW202425971A (zh) 三環類化合物及其製備方法和應用
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK1234395B (zh) 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220323

R150 Certificate of patent or registration of utility model

Ref document number: 7046959

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250